Don’t miss the latest developments in business and finance.

Novel Laboratories concludes USFDA inspection with 13 observations

Image
Capital Market
Last Updated : Nov 09 2020 | 10:16 AM IST
Lupin announced that the company's subsidiary Novel Laboratories Inc. based in Somerset, NJ has just concluded a U.S. FDA inspection. The inspection commenced on 10 September 2020 and concluded on 05 November 2020. The duration of the inspection was prolonged due to COVID-related delays and challenges.

The inspection at the Somerset, NJ facility closed with thirteen observations. The company is confident of addressing these observations and will work closely with the agency to address their concerns.

The Company does not believe that this will have an impact on disruption of supplies or the existing revenues from operations of this facility. The facility contributes less than 5 percent of its global revenues.

Powered by Capital Market - Live News

Also Read

First Published: Nov 09 2020 | 9:55 AM IST

Next Story